Acute myeloid leukemia stratifies as 2 clinically relevant sphingolipidomic subtypes

摘要: COI notes: ADV is a scientific advisor to Arima Genomics. BMB is the owner/founder of Tahosa Bio, LLC (Rapid City, SD). MST has received research funding from AbbVie, Orsenix, BioSight, Glycomimetics, Rafael Pharmaceuticals, and Amgen; is on the advisory boards for AbbVie, Daiichi-Sankyo, Orsenix, KAHR, Oncolyze, Jazz Pharma, Roche, BioSight, Novartis, Innate Pharma, Kura, Syros Pharmaceuticals, Ipsen Biopharmaceuticals, Cellularity; has received royalties from UpToDate (for writing); is Chair for the Data and Safety Monitoring Board (DSMB) for HOVON 156; is Chair of the Adjudication Committee for Foghorn Therapeutics; has received honoraria from Northwell Health, Japan Society of Hematology, MetroHealth Cleveland, Ohio State University, American Society of Hematology; and is on the Board for the American Society of Hematology. RLL is on the supervisory board of Qiagen; is a scientific …